|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY
Henry Ford Hospital, Detroit, Michigan (M.G., J.D.F., S.L.B., A.S.A., P.A.E.); Medical College of Wisconsin, Milwaukee, Wisconsin (R.J.R.); University of Texas Southwestern Medical Center, Dallas, Texas (J.R.F.); and Henry Ford Hospital and Wayne State University, Detroit, Michigan (A.G.S.)
The present study examined the effects of N-hydroxy-N'-(4-butyl-2 methylphenyl) formamidine (HET0016), a selective inhibitor of the formation of 20-hydroxyeicosatrienoic acid (20-HETE) on the growth of 9L rat gliosarcoma cells in vitro and in vivo. After 48 h of incubation, HET0016 reduced the proliferation of 9L in vitro by 55%, and this was associated with a fall in p42/p44 mitogen-activated protein kinase and stress-activated protein kinase/c-Jun NH2-terminal kinase phosphorylation and increased apoptosis. HET0016 inhibited epidermal growth factor (EGF) and platelet-derived growth factor (PDGF)-induced proliferation and diminished phosphorylation of PDGF receptors. A stable 20-HETE analog increased 9L cell proliferation. In vivo, chronic administration of HET0016 (10 mg/kg/day i.p.) for 2 weeks reduced the volume of 9L tumors by 80%. This was accompanied by a 4-fold reduction in the mitotic index, a 3- to 4-fold increase in the apoptotic index, and a
50% decrease in vascularization in the tumor. HET0016 treatment increased mean survival time of the animals from 17 to 22 days. Liquid chromatography/mass spectrometry experiments indicated that neither 9L cells grown in vitro nor 9L tumors removed produce 20-HETE when incubated with arachidonic acid. The normal surrounding brain tissue, however, avidly makes 20-HETE, and this activity is selectively inhibited by HET0016. These results suggest that HET0016 may be the prototype of a class of antigrowth compounds that may be efficacious for treating malignant brain tumors. In vivo, it may act in part by inhibiting the formation of 20-HETE by the surrounding tissue. However, the antiproliferative effects of HET0016 on 9L cells in vitro seem unrelated to its ability to inhibit the formation of 20-HETE.
Address correspondence to: Dr. Meng Guo, Eye Care Services, Henry Ford Hospital, One Ford Place, 4 D, Detroit, MI 48202-3450. E-mail: mguo1{at}hfhs.org
This article has been cited by other articles:
![]() |
A. ALEXANIAN, V. A. RUFANOVA, B. MILLER, A. FLASCH, R. J. ROMAN, and A. SOROKIN Down-regulation of 20-HETE Synthesis and Signaling Inhibits Renal Adenocarcinoma Cell Proliferation and Tumor Growth Anticancer Res, October 1, 2009; 29(10): 3819 - 3824. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Akbulut, K. R. Regner, R. J. Roman, E. D. Avner, J. R. Falck, and F. Park 20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR- and c-Src-dependent mechanism Am J Physiol Renal Physiol, September 1, 2009; 297(3): F662 - F670. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Park, W. E. Sweeney Jr., G. Jia, T. Akbulut, B. Mueller, J. R. Falck, S. Birudaraju, R. J. Roman, and E. D. Avner Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD Am J Physiol Renal Physiol, March 1, 2009; 296(3): F575 - F582. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dhanasekaran, S. Bodiga, S. Gruenloh, Y. Gao, L. Dunn, J. R. Falck, J. N. Buonaccorsi, M. Medhora, and E. R. Jacobs 20-HETE increases survival and decreases apoptosis in pulmonary arteries and pulmonary artery endothelial cells Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H777 - H786. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Park, W. E. Sweeney, G. Jia, R. J. Roman, and E. D. Avner 20-HETE Mediates Proliferation of Renal Epithelial Cells in Polycystic Kidney Disease J. Am. Soc. Nephrol., October 1, 2008; 19(10): 1929 - 1939. [Abstract] [Full Text] [PDF] |
||||